losartan has been researched along with uric acid in 123 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (18.70) | 18.2507 |
| 2000's | 50 (40.65) | 29.6817 |
| 2010's | 41 (33.33) | 24.3611 |
| 2020's | 9 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Grassl, SM; Holtzman, EJ; Race, JE; Williams, WJ | 1 |
| Kanamaru, M; Kosuge, K; Nakashima, M; Uematsu, T | 1 |
| Goldberg, AI; Pratt, JH; Soffer, BA; Sweet, CS; Wiens, B; Wright, JT | 1 |
| Brunner, HR; Burnier, M; Nussberger, J; Pechère-Bertschi, A; Waeber, B | 1 |
| Berman, RS; Bradstreet, DC; Jallard, N; Saenz, A; Sweet, CS; Weidler, DJ | 1 |
| de Jong, PE; de Zeeuw, D; Gansevoort, RT; Redfield, A; Shahinfar, S | 1 |
| Brunner, HR; Burnier, M; Nussberger, J; Rutschmann, B; Shahinfar, S; Versaggi, J; Waeber, B | 1 |
| Edwards, RM; Stack, EJ; Trizna, W; Weinstock, J | 1 |
| Freel, RW; Hatch, M; Shahinfar, S; Vaziri, ND | 1 |
| Ebihara, A; Fujimura, A; Harada, K; Sasaki, M; Sunaga, K | 1 |
| Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P | 1 |
| Barrows, S; Dunn, MJ; Meibohm, A; Shahinfar, S; Simpson, RL; Smith, MC; Weigel, K | 1 |
| Brunner, HR; Burnier, M | 1 |
| Diezi, J; Guisan, B; Roch-Ramel, F | 1 |
| Burnier, M; Goy, JJ; Minghelli, G; Seydoux, C | 1 |
| Beevers, DG; Lip, GY | 1 |
| Ikemoto, F; Nishikibe, M | 1 |
| Bairaktari, E; Elisaf, M; Siamopoulos, KC; Tsimichodimos, V | 1 |
| Boran, M; Cetin, S; Gönen, F | 1 |
| Ikemoto, F; Nishikibe, M; Ohta, H; Satomi, T; Suzuki, J | 1 |
| Carides, AD; Coe, FL; Nakagawa, Y; Parks, JH; Shahinfar, S; Simpson, RL; Thiyagarajan, B; Umans, JG | 1 |
| Alderman, M | 1 |
| Fitzgerald, D; Kelly, L; Nallen, R; O'Brien, E; Owens, P; Ryan, D | 1 |
| Benemio, G; Bruni, B; Porcellati, C; Reboldi, GP; Sacchi, N; Schillaci, G; Verdecchia, P | 1 |
| Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N | 1 |
| Elisaf, MS; Milionis, HJ | 1 |
| Böhmig, G; Gruber, U; Köller, E; Mayer, G; Schmidt, A | 1 |
| Barceló, P; Calero, F; Cases, A; Mora-Macía, J | 1 |
| Aznar, J; Llisterri, JL; Lozano, JV; Redon, J | 1 |
| Kamper, AL; Nielsen, AH | 1 |
| Calhoun, DA; DeLucca, PT; Elliott, WJ; Gazdick, LP; Kerns, DE; Zeldin, RK | 1 |
| Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G | 1 |
| Elisaf, MS; Milionis, HJ; Nikas, S | 1 |
| Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 1 |
| Christides, D; Elisaf, M; Liberopoulos, E | 1 |
| Bairaktari, E; Elisaf, M; Kalaitzidis, R; Milionis, H; Nikas, S; Rizos, E; Siamopoulos, K | 1 |
| Badowski, R; Cieślik, P; Haczkiewicz, P; Hefczyc, J; Hrycek, A; Scieszka, J | 1 |
| Chen, Q; Feng, L; Gordon, KL; Han, L; Johnson, RJ; Kanellis, J; Kang, DH; Lan, HY; Mazzali, M; Nakagawa, T; Watanabe, S; Xia, YY | 1 |
| Armada, E; Gayoso, P; Otero Glz, A; Pérez Melón, C | 1 |
| Puig, JG; Ruilope, LM; Torres, R | 1 |
| Schoolwerth, AC; Sica, DA | 1 |
| Furuse, M; Hamada, T; Hisatome, I; Igawa, O; Kinugasa, Y; Matsubara, K; Ohtahara, A; Shigemasa, C; Shimizu, H; Sonoyama, K; Tanaka, H; Yamamoto, T; Yamamoto, Y | 1 |
| Cho, BH; Kang, SK; Kim, W; Lee, S; Park, SK; Yu, HC | 1 |
| Takagi, K; Tsutani, H | 1 |
| Hasegawa, Y; Ito, O; Ito, S; Kudo, K; Mitsui, H; Sato, H; Sato, K; Yuda, F | 1 |
| Chen, C; Snapinn, SM; Wang, H | 1 |
| Alderman, MH; Chen, C; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H | 1 |
| Aiyer, KJ; Alderman, M | 1 |
| Bomalaski, JS; Clark, MA | 1 |
| Athyros, VG; Daskalopoulou, SS; Elisaf, M; Mikhailidis, D | 1 |
| Alderman, M; Redfern, JS | 1 |
| Høieggen, A; Kjeldsen, SE; Os, I | 1 |
| Chen, G; Dang, A; Liu, G; Song, W; Wang, B; Zhang, Y | 1 |
| Daskalopoulou, SS; Elisaf, M; Mikhailidis, DP; Tzovaras, V | 1 |
| Inokuchi, T; Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 1 |
| Baines, D; Isaacs, S; Opie, LH; Rayner, BL; Trinder, YA | 1 |
| Chrysant, GS; Chrysant, SG | 1 |
| Aksnes, TA; Guptha, S; Kjeldsen, SE; Moan, A; Os, I; Reims, HM | 1 |
| Leary, WP; Reyes, AJ | 1 |
| Iwanaga, T; Maeda, T; Ogihara, T; Sato, M; Tamai, I | 1 |
| Chen, GL; Dang, AM; Liu, GZ; Zhang, YH | 1 |
| Perez-Ruiz, F | 1 |
| Hirayama, Y; Matsuoka, H; Nonaka, K; Ogihara, T; Saruta, T; Suzuki, H; Takahashi, K; Toki, M | 1 |
| Abe, H; Fujiwara, H; Hiei, K; Kakami, M; Minagawa, T; Minatoguchi, S; Murata, I; Nagano, T; Ohashi, H; Okuma, T; Osumi, Y; Takatsu, H; Takaya, T; Tanaka, T; Tsukamoto, T; Yokoyama, H | 1 |
| Boomsma, F; de Zeeuw, D; Navis, G; Vogt, L; Waanders, F | 1 |
| Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N | 1 |
| Hisatome, I; Igawa, O; Ogino, K | 1 |
| Hamada, T; Hisatome, I; Hosoya, T; Hosoyamada, M; Ichida, K; Igawa, O; Mizuta, E; Ninomiya, H; Ohtahara, A; Shigamasa, C; Sonoyama, K; Sugihara, S; Yamamoto, Y; Yanagihara, K | 1 |
| Brunner, HR; Burnier, M; Waeber, B | 1 |
| Cseh, J; Csiky, B; Markó, L; Mikolás, E; Mohás, M; Szíjártó, I; Wittmann, I | 1 |
| Bibert, S; Bonny, O; Firsov, D; Geering, K; Hess, SK; Horisberger, JD; Thorens, B | 1 |
| Chen, J; Cheng, M; Ding, X; Han, F; Le, Y; Xu, L; Zhang, L; Zhu, X | 1 |
| Hamada, T; Hirai, M; Hisatome, I; Igawa, O; Kato, M; Kondo, T; Mizuta, E; Ninomiya, H; Shigemasa, C; Yamada, K; Yamamoto, Y | 1 |
| Hong, N; Kang, SM; Oh, J | 1 |
| Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP | 1 |
| Bahrudin, U; Hamada, T; Hisatome, I; Hosoyamada, M; Ichida, K; Igawa, O; Iwai, C; Kuwabara, M; Kuwabara, N; Mizuta, E; Nindita, Y; Ninomiya, H; Shigemasa, C; Tsuchihashi, T; Urashima, S; Utami, SB; Yamada, K | 1 |
| Albertoni, G; Barreto, JA; Borges, F; Maquigussa, E; Pessoa, E; Schor, N | 1 |
| Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A | 1 |
| Brenner, BM; Cooper, ME; de Zeeuw, D; Grobbee, DE; Lambers Heerspink, HJ; Laverman, GD; Miao, Y; Ottenbros, SA; Parving, HH; Shahinfar, S | 1 |
| Doria, A; Krolewski, AS | 1 |
| Dawson, J; Walters, M | 1 |
| Carmona, L; Herrero-Beites, AM; Perez-Ruiz, F | 1 |
| Ahmed, SB; Beaudin, AE; Foster, GE; Hanly, PJ; Pialoux, V; Poulin, MJ | 1 |
| Kohagura, K; Nakada, S; Ohshiro, K; Ohya, Y; Sakima, A; Tana, T; Yamazato, M | 1 |
| Islam, F; Jamali, SN; Khan, M; Khan, RA; Laghari, J | 1 |
| Dhaun, N; Webb, DJ | 1 |
| Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T | 1 |
| Eto, K; Fujimori, S; Ogata, N; Oka, Y | 1 |
| Hong, E; Moreno, JA | 1 |
| Bakker, SJ; Berl, T; Cooper, ME; de Zeeuw, D; Lambers Heerspink, HJ; Laverman, GD; Smink, PA | 1 |
| Imaizumi, T; Kai, H; Ueda, T | 1 |
| Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N | 1 |
| Inou, T; Kobayashi, K; Kubara, I; Meno, H; Nakamura, Y; Ota, T; Shiga, Y; Tanaka, M; Tsuchiya, Y | 1 |
| Hosoya, T; Kobayashi, A; Kuriyama, S; Ohno, I; Otsuka, Y; Yoshizawa, T | 1 |
| Baba, Y; Fukuda, M; Kato, S; Maeda, K; Nishi, S; Nishimura, H; Ohashi, S; Okuda, J; Otoshi, K; Shintani, M | 1 |
| Hanaoka, K; Hasegawa, T; Kaizu, K; Kamata, K; Kimura, K; Kobayashi, S; Morita, S; Ohtake, T; Oshikawa, J; Sato, T; Taguri, M; Toya, Y; Umemura, S; Yasuda, G | 1 |
| Hamada, T; Haruaki, N; Hirota, Y; Hisatome, I; Kato, M; Kosaka, H; Kotake, H; Kuwabara, M; Miyazaki, S; Mizuta, E; Nakamura, H; Ogino, K; Ohtahara, A; Omodani, H; Taniguchi, S; Watanabe, A; Watanabe, M; Yamamoto, K | 1 |
| Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH | 1 |
| Asai, S; Kanou, N; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y | 1 |
| Kirch, W; Saar, J | 1 |
| Arakawa, M; Endo, M; Hidaka, S; Kanda, N; Kanmatsuse, K; Kurosawa, Y; Odani, T; Uchida, N; Yamazaki, T | 1 |
| Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K | 1 |
| Arima, H; Fujii, K; Fukuhara, M; Kato, I; Kawasaki, J; Matsumura, K; Morinaga, Y; Ohta, Y; Ohtsubo, T; Otonari, T; Sasaguri, T; Tominaga, M; Tsuchihashi, T; Uezono, K | 1 |
| Fujisawa, K; Hitaka, Y; Inoue, A; Koyoshi, R; Kuwano, T; Matsunaga, E; Miura, S; Morii, J; Nagata, I; Norimatsu, K; Saku, K; Shiga, Y; Shirotani, T; Uehara, Y | 1 |
| Ren, Q; Wu, W; Yu, S | 1 |
| de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B | 1 |
| Ding, Y; Li, N; Miao, P; Zheng, H | 1 |
| Anzai, N; Hamada, T; Hirota, Y; Hisatome, I; Ikeda, N; Kato, M; Kuwabara, M; Maharani, N; Mishima, M; Miyazaki, S; Mizuta, E; Ninomiya, H; Notsu, T; Ogino, K; Onohara, T; Otani, N; Sugihara, S; Yoshida, A | 1 |
| Çetin, A; Kırça, M; Oğuz, N; Uzuner, F; Yeşilkaya, A | 1 |
| Duran-Salgado, MB; Elizalde-Barrera, CI; Garro-Almendaro, AK; Rubio-Guerra, AF; Suarez-Cuenca, JA | 1 |
| Çetin, A; Kırça, M; Oğuz, N; Yeşilkaya, A | 1 |
| Daneshtalab, N; Smeda, JS | 1 |
| Ashcroft, JA | 1 |
| Kelly, TC; Nagel, AK; Shoales, LA; Sutton Burke, EM | 1 |
| Kim, H; Kim, HS; Kim, JH; Lee, SH | 1 |
| Bryant, CE; Hogg, RJ; Rajai, A; Webb, NJA | 1 |
| Majer, J; Masajtis-Zagajewska, A; Nowicki, M | 1 |
| An, H; Choi, J; Joo, HJ; Kim, EJ; Kim, YH; Lee, J; Yum, Y | 1 |
| Akmalova, KA; Asoskova, AV; Boyarko, AV; Fisenko, VP; Grishina, EA; Mirzaev, KB; Sinitsina, II; Sozaeva, ZA; Sychev, DA; Temirbulatov, II | 1 |
| Ferreira, JP; Kiernan, MS; Konstam, MA; Zannad, F | 1 |
| Appel, LJ; Castilla-Ojo, N; Conlin, PR; Juraschek, SP; Miller, ER; Turkson-Ocran, RA | 1 |
| Bai, J; Cai, L; Miao, Z; Si, Y; Sun, J; Wei, Y; Xiao, Y; Xing, W; Ye, H | 1 |
18 review(s) available for losartan and uric acid
| Article | Year |
|---|---|
Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Humans; Imidazoles; Kidney; Kidney Tubules; Losartan; Natriuresis; Potassium; Renal Circulation; Renin-Angiotensin System; Tetrazoles; Uric Acid | 1996 |
[Pharmacological properties and its significance in clinical practice].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Humans; Losartan; Receptors, Thromboxane; Uric Acid | 1999 |
[Pharmacological characteristics and clinical application of losartan, an orally active AT1 angiotensin II receptor antagonist].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Chronic Disease; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Losartan; Proteinuria; Rats; Receptors, Thromboxane; Renin-Angiotensin System; Uric Acid | 1999 |
Uric acid in hypertension and cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Blood Pressure; Coronary Disease; Humans; Hypertension; Incidence; Losartan; Risk Factors; Survival Rate; Uric Acid | 1999 |
Part 1. Uric acid and losartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood; Humans; Kidney; Losartan; Uric Acid | 2002 |
[Typing of hypouricemia (uric acid clearance)].
Topics: Allopurinol; Creatinine; Humans; Inappropriate ADH Syndrome; Kidney Diseases; Kidney Tubules; Losartan; Metabolic Clearance Rate; Purine-Nucleoside Phosphorylase; Purine-Pyrimidine Metabolism, Inborn Errors; Uric Acid; Xanthine Oxidase | 2003 |
Uric acid: role in cardiovascular disease and effects of losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hyperuricemia; Kidney Diseases; Losartan; Purines; Treatment Outcome; Uric Acid | 2004 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Losartan; Pyrazoles; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid; Xanthine Oxidase | 2004 |
[Serum uric acid--a cardiovasular risk factor?].
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hyperuricemia; Losartan; Risk Factors; Uric Acid; Uricosuric Agents | 2004 |
[Uric acid--more deleterious than we thought?].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Kidney; Losartan; Male; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Uric Acid | 2005 |
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Losartan; Pyrroles; Uric Acid | 2005 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Diabetes Mellitus; Heart; Humans; Kidney; Losartan; Platelet Aggregation; Stroke; Tetrazoles; Uric Acid; Valine; Valsartan | 2006 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Hypolipidemic Agents; Losartan; Uric Acid | 2008 |
Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Glomerular Filtration Rate; Heart Rate; Humans; Losartan; Renin; Renin-Angiotensin System; Uric Acid | 1995 |
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Losartan; Risk Factors; Uric Acid; Xanthine Oxidase | 2006 |
[Lozartan potential in hyperuricemia correction].
Topics: Antihypertensive Agents; Humans; Hypertension; Hyperuricemia; Losartan; Metabolic Syndrome; Uric Acid | 2011 |
Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Chi-Square Distribution; Cough; Creatinine; Enalapril; Female; Humans; Kidney; Losartan; Male; Middle Aged; Odds Ratio; Renal Insufficiency, Chronic; Renin-Angiotensin System; Risk Factors; Treatment Outcome; Uric Acid | 2013 |
Angiotensin Receptor Blockers Effect on Serum Uric Acid-A Class Effect?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Humans; Hypertension; Losartan; Tetrazoles; Uric Acid | 2020 |
56 trial(s) available for losartan and uric acid
| Article | Year |
|---|---|
Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects.
Topics: Adult; Angiotensin Receptor Antagonists; Biphenyl Compounds; Creatinine; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunoenzyme Techniques; Losartan; Male; Pilot Projects; Reference Values; Tetrazoles; Uric Acid | 1992 |
Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diastole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Posture; Potassium; Systole; Tetrazoles; Time Factors; Uric Acid | 1995 |
Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Imidazoles; Injections, Intravenous; Kidney Function Tests; Losartan; Male; Middle Aged; Renin; Tetrazoles; Uric Acid | 1994 |
Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Imidazoles; Longitudinal Studies; Losartan; Male; Proteinuria; Renal Circulation; Single-Blind Method; Tetrazoles; Uric Acid | 1994 |
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
Topics: Adult; Aldosterone; Angiotensin II; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Electrolytes; Glomerular Filtration Rate; Hemodynamics; Humans; Imidazoles; Kidney; Lithium; Losartan; Male; Renal Circulation; Renin; Sodium, Dietary; Tetrazoles; Uric Acid; Urine | 1993 |
Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Administration Schedule; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Pulse; Tetrazoles; Uric Acid | 1996 |
Effects of losartan on renal function in patients with essential hypertension.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Imidazoles; Kidney; Losartan; Male; Middle Aged; Renal Circulation; Single-Blind Method; Sodium; Tetrazoles; Uric Acid | 1996 |
The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Humans; Hypertension; Imidazoles; Kidney; Losartan; Middle Aged; Prostaglandins; Renin; Single-Blind Method; Tetrazoles; Uric Acid | 1995 |
Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Cross-Over Studies; Double-Blind Method; Enalapril; Heart Transplantation; Humans; Losartan; Male; Middle Aged; Uric Acid; Uricosuric Agents | 1998 |
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Benzothiadiazines; Diuretics; Double-Blind Method; Female; Humans; Hydrogen-Ion Concentration; Hypertension; Losartan; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Uric Acid | 1999 |
Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide--a randomized controlled trial.
Topics: Antihypertensive Agents; Blood Platelets; Blood Pressure; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Treatment Outcome; Uric Acid | 2000 |
Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carrier Proteins; Case-Control Studies; Diuretics; Drug Synergism; Drug Therapy, Combination; Echocardiography; Enalapril; Female; Follow-Up Studies; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Sodium Chloride Symporter Inhibitors; Uric Acid; Ventricular Function, Left | 2000 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hypertension, Renal; Kidney; Losartan; Male; Middle Aged; Prospective Studies; Sodium Chloride Symporter Inhibitors; Uric Acid | 2000 |
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Cyclosporine; Enalapril; Female; Homeostasis; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Potassium; Prospective Studies; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Uric Acid | 2001 |
Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Creatinine; Diastole; Disease Progression; Female; Follow-Up Studies; Hemoglobins; Humans; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Proteinuria; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Systole; Time Factors; Uric Acid | 2001 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hydrochlorothiazide; Hypertension; Losartan; Regression Analysis; Systole; Uric Acid | 2001 |
Uricosuric effect of losartan in patients with renal transplants.
Topics: Adult; Angiotensin Receptor Antagonists; Cross-Over Studies; Cyclosporine; Drug Administration Schedule; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Reference Values; Uric Acid | 2001 |
Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2001 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind Method; Gout; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Prospective Studies; Tetrazoles; Uric Acid | 2001 |
The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hypertension; Indapamide; Losartan; Male; Middle Aged; Uric Acid | 2000 |
[Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Bilirubin; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Potassium; Sodium; Time Factors; Treatment Outcome; Triglycerides; Uric Acid; Ventricular Function, Left | 2001 |
AT1 blockers and uric acid metabolism: are there relevant differences?
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Double-Blind Method; Humans; Hypertension; Imidazoles; Losartan; Receptor, Angiotensin, Type 1; Thiophenes; Uric Acid | 2002 |
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist therapy in hypertensive renal transplant recipients.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Creatinine; Drug Therapy, Combination; Enalapril; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Postoperative Complications; Potassium; Proteinuria; Receptor, Angiotensin, Type 1; Uric Acid | 2002 |
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; Endpoint Determination; Female; Follow-Up Studies; Hemoglobins; Humans; Hypertension, Renal; Losartan; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Treatment Outcome; Uric Acid | 2004 |
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Biphenyl Compounds; Blood Pressure; China; Double-Blind Method; Female; Humans; Hypertension; Hyperuricemia; Incidence; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Treatment Outcome; Uric Acid | 2006 |
Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases.
Topics: Adult; Antihypertensive Agents; Cholesterol; Dose-Response Relationship, Drug; Fenofibrate; Humans; Hypolipidemic Agents; Hypoxanthine; Losartan; Male; Metabolic Clearance Rate; Middle Aged; Time Factors; Triglycerides; Uric Acid; Xanthine | 2006 |
Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diuretics; Female; Fibrinogen; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Hyperuricemia; Losartan; Male; Tetrazoles; Treatment Outcome; Uric Acid | 2006 |
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Female; Glucose Clamp Technique; Heart Rate; Humans; Hypertension; Insulin; Insulin Resistance; Lipids; Losartan; Male; Middle Aged; Risk Factors; Treatment Outcome; Uric Acid; Vasodilation | 2006 |
[The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Uric Acid | 2006 |
Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Japan; Losartan; Male; Middle Aged; Potassium; Uric Acid | 2007 |
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Losartan; Male; Middle Aged; Treatment Failure; Uric Acid | 2007 |
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Lipids; Losartan; Male; Middle Aged; Patient Compliance; Potassium; Proteinuria; Renin; Renin-Angiotensin System; Serum Albumin; Sodium Chloride, Dietary; Uric Acid | 2008 |
Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Case-Control Studies; Cyclosporine; Female; Humans; Hyperuricemia; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Polycythemia; Prospective Studies; Receptor, Angiotensin, Type 1; Safety; Uric Acid | 2009 |
Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Diuretics; Double-Blind Method; Female; Humans; Hypertension; Lipids; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Uric Acid | 2010 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors; Uric Acid | 2010 |
Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
Topics: Adult; Angiotensin Receptor Antagonists; Blood Pressure; China; Creatinine; Drug Synergism; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Longitudinal Studies; Losartan; Male; Prospective Studies; Proteinuria; Ribonucleosides; Treatment Outcome; Uric Acid | 2011 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Losartan; Male; Middle Aged; Risk Factors; Time Factors; Treatment Outcome; Uric Acid | 2011 |
Losartan abolishes oxidative stress induced by intermittent hypoxia in humans.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Cross-Over Studies; Deoxyguanosine; Double-Blind Method; Humans; Hypoxia; Losartan; Male; Nitric Oxide; Oxidative Stress; Tyrosine; Uric Acid | 2011 |
To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
Topics: Aged; Humans; Hydrochlorothiazide; Hypertension; Hyperuricemia; Kidney; Losartan; Middle Aged; Sodium Chloride Symporter Inhibitors; Treatment Outcome; Uric Acid; Uricosuric Agents | 2011 |
Effects of losartan/hydrochlorothiazide on serum uric acid levels and blood pressure in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Uric Acid | 2011 |
An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular System; Data Interpretation, Statistical; Diabetic Nephropathies; Female; Humans; Irbesartan; Losartan; Male; Middle Aged; Placebos; Proportional Hazards Models; Risk; Risk Factors; Tetrazoles; Treatment Outcome; Uric Acid | 2012 |
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension--a prospective, randomized, open-labeled, parallel-group, multicenter trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Uric Acid | 2012 |
Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Uric Acid | 2012 |
Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Multivariate Analysis; Treatment Outcome; Uric Acid | 2012 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Hyperuricemia; Losartan; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2013 |
Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome; Uric Acid; Young Adult | 2014 |
A comparative study on the effectiveness of losartan/hydrochlorothiazide and telmisartan/hydrochlorothiazide in patients with hypertension.
Topics: Adult; Aged; Benzimidazoles; Benzoates; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Prospective Studies; Telmisartan; Treatment Outcome; Uric Acid | 2014 |
Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
Topics: Adult; Aged; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Young Adult | 2014 |
Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diuretics; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Treatment Outcome; Uric Acid | 2015 |
Efficacy and safety of combination therapy of high-dose losartan and hydrochlorothiazide in patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Creatinine; Diastole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Potassium; Systole; Treatment Outcome; Uric Acid | 2015 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pressure; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Individuality; Irbesartan; Kidney; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Potassium; Prospective Studies; Risk Factors; Tetrazoles; Uric Acid | 2015 |
Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Time Factors; Treatment Outcome; Uric Acid | 2017 |
Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria.
Topics: Adult; Antihypertensive Agents; Child; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; Losartan; Prospective Studies; Proteinuria; Uric Acid | 2021 |
Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.
Topics: Acrylates; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Fructose; Humans; Hypertension; Imidazoles; Losartan; Metabolic Syndrome; Middle Aged; Thiophenes; Uric Acid | 2021 |
High- versus low-dose losartan and uric acid: An analysis from HEAAL.
Topics: Heart Failure; Humans; Hyperuricemia; Losartan; Stroke Volume; Uric Acid; Ventricular Function, Left | 2023 |
Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.
Topics: Adult; Dietary Approaches To Stop Hypertension; Female; Gout; Humans; Hypertension; Hyperuricemia; Losartan; Male; Middle Aged; Uric Acid | 2023 |
49 other study(ies) available for losartan and uric acid
| Article | Year |
|---|---|
Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
Topics: Amino Acid Sequence; Animals; Anion Transport Proteins; Biological Transport; Blotting, Northern; Carrier Proteins; Chromosomes, Human, Pair 11; Cloning, Molecular; Humans; Kidney; Mice; Molecular Sequence Data; Oocytes; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Rats; Sequence Homology, Amino Acid; Xenopus laevis | 1999 |
Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
Topics: Adult; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Kidney; Kidney Tubules; Losartan; Natriuresis; Potassium; Renin-Angiotensin System; Sodium; Sodium, Dietary; Tetrazoles; Uric Acid; Vasomotor System; Water | 1995 |
Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Transport; Biphenyl Compounds; Carbon Radioisotopes; Hydrogen-Ion Concentration; Imidazoles; Kidney; Kinetics; Losartan; Male; Microvilli; Naphthalenes; Rats; Rats, Sprague-Dawley; Tetrazoles; Thiophenes; Uric Acid | 1996 |
Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Transport; Biphenyl Compounds; Chlorides; Colon; Homeostasis; Imidazoles; Intestinal Absorption; Kidney; Kidney Failure, Chronic; Losartan; Male; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Urate Oxidase; Uric Acid; Xanthine Oxidase | 1996 |
Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles.
Topics: Aged; Benzbromarone; Biological Transport; Biphenyl Compounds; Carbon Radioisotopes; Diuretics; Ethambutol; Humans; Imidazoles; Kidney Cortex; Kidney Neoplasms; Kinetics; Losartan; Microvilli; Middle Aged; Probenecid; Pyrazinamide; Salicylates; Salicylic Acid; Sulfinpyrazone; Tetrazoles; Ticrynafen; Uric Acid; Uricosuric Agents | 1997 |
Is uric acid really an independent cardiovascular risk factor?
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Losartan; Male; Risk Factors; Ticrynafen; Uric Acid | 1998 |
Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Blood Chemical Analysis; Female; Fenofibrate; Humans; Hypertension; Hypolipidemic Agents; Losartan; Male; Middle Aged; Polypharmacy; Uric Acid | 1999 |
Losartan in renal allograft recipients receiving cyclosporine A.
Topics: Adult; Angiotensin Receptor Antagonists; Cyclosporine; Drug Evaluation; Erythropoiesis; Female; Hematocrit; Hemoglobins; Humans; Kidney Transplantation; Losartan; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Uric Acid | 1999 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Losartan; Male; Middle Aged; Risk Factors; Sodium Chloride Symporter Inhibitors; Uric Acid | 2000 |
Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients.
Topics: Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Losartan; Sodium Chloride Symporter Inhibitors; Uric Acid | 2001 |
Effect of losartan and furosemide on the urinary excretion of oxypurinol and uric acid.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Proteins; Diuretics; Furosemide; Humans; Losartan; Male; Middle Aged; Oxypurinol; Uric Acid; Xanthine Oxidase | 2000 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Topics: Antihypertensive Agents; Biphenyl Compounds; Gout; Humans; Hypertension; Irbesartan; Losartan; Tetrazoles; Uric Acid | 2002 |
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.
Topics: Administration, Oral; Allopurinol; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arterioles; Benzofurans; Blood Pressure; Diuretics; Enalapril; Hydrochlorothiazide; Hypertension; Kidney; Losartan; Male; Muscle, Smooth, Vascular; Oxonic Acid; Rats; Rats, Sprague-Dawley; Sodium Chloride Symporter Inhibitors; Sodium Chloride, Dietary; Uric Acid; Uricosuric Agents; Vascular Diseases | 2002 |
[Uricemia-lowering activity of losartan in kidney transplantation].
Topics: Adult; Cyclosporine; Drug Evaluation; Erythroid Precursor Cells; Erythropoietin; Humans; Immunosuppressive Agents; Kidney Transplantation; Kidney Tubules; Losartan; Middle Aged; Polycythemia; Postoperative Complications; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renal Circulation; Treatment Outcome; Uric Acid | 2002 |
Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Enalapril; Humans; Hypoxanthine; Losartan; Male; Oxypurinol; Uric Acid; Xanthine | 2002 |
A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide.
Topics: Acute Kidney Injury; Antihypertensive Agents; Benzbromarone; Blood Cell Count; Creatinine; Diuretics; Drug Therapy, Combination; Exercise; Humans; Hypertension; Kidney; Kidney Function Tests; Losartan; Male; Martial Arts; Middle Aged; Pyrazinamide; Sodium Chloride Symporter Inhibitors; Trichlormethiazide; Uric Acid | 2003 |
Proportion of treatment effect (PTE) explained by a surrogate marker.
Topics: Antihypertensive Agents; Atenolol; Biomarkers; Confidence Intervals; Data Interpretation, Statistical; Humans; Hypertension; Losartan; Models, Statistical; Monte Carlo Method; Treatment Outcome; Uric Acid | 2003 |
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension, Renal; Losartan; Uric Acid | 2004 |
Hypertension, diuretics, and uric acid.
Topics: Antihypertensive Agents; Antioxidants; Benzimidazoles; Biphenyl Compounds; Cardiovascular System; Diuretics; Humans; Hypertension; Losartan; Reactive Oxygen Species; Tetrazoles; Uric Acid | 2006 |
Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Female; Imidazoles; Losartan; Organic Anion Transporters; Organic Cation Transport Proteins; Pyrazinamide; Tetrazoles; Uric Acid; Valine; Valsartan; Xenopus laevis | 2007 |
New treatments for gout.
Topics: Allopurinol; Ascorbic Acid; Female; Fenofibrate; Gout; Gout Suppressants; Humans; Losartan; Male; Sensitivity and Specificity; Urate Oxidase; Uric Acid | 2007 |
Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Female; Follow-Up Studies; Humans; Hypertension; Losartan; Male; Middle Aged; Prospective Studies; Uric Acid | 2008 |
Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; DNA; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypertension; Hyperuricemia; Losartan; Male; Mutation; Organic Anion Transporters; Organic Cation Transport Proteins; Polymerase Chain Reaction; Tetrazoles; Treatment Outcome; Uric Acid | 2008 |
[The pleiotropic effects of losartan--the importance of decreasing uric acid level].
Topics: Antihypertensive Agents; Humans; Hypertension; Losartan; Uric Acid; Uricosuric Agents | 2008 |
Mouse GLUT9: evidences for a urate uniporter.
Topics: Animals; Benzbromarone; Biological Transport; Chlorides; Glucose; Glucose Transport Proteins, Facilitative; Glucose Transporter Type 2; Kinetics; Losartan; Male; Membrane Potentials; Mice; Mice, Inbred C57BL; Nephrons; Oocytes; Organic Anion Transporters; Phloretin; Protein Isoforms; RNA, Messenger; Sodium; Species Specificity; Uric Acid; Uricosuric Agents; Xenopus laevis | 2009 |
High-dose versus low-dose losartan in patients with heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Losartan; Uric Acid | 2010 |
Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzbromarone; Cell Line; Humans; Kidney; Losartan; Organic Anion Transporters; Organic Cation Transport Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Uric Acid; Uricosuric Agents | 2010 |
Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Calcium; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Humans; Losartan; Mesangial Cells; Polymerase Chain Reaction; Uric Acid | 2010 |
Diabetes: Lowering serum uric acid levels to prevent kidney failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetic Nephropathies; Humans; Hyperuricemia; Kidney Failure, Chronic; Losartan; Uric Acid | 2011 |
A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Topics: Aged; Cohort Studies; Colchicine; Crystallization; Female; Fenofibrate; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Kaplan-Meier Estimate; Losartan; Male; Middle Aged; Prospective Studies; Regression Analysis; Secondary Prevention; Time Factors; Treatment Outcome; Uric Acid; Withholding Treatment | 2011 |
Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hydrogen-Ion Concentration; Hypertension; Hyperuricemia; Losartan; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Treatment Outcome; Uric Acid | 2011 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hypertension; Losartan; Male; Uric Acid | 2012 |
Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Creatinine; Drug Combinations; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hypertension; Hyperuricemia; Japan; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Treatment Outcome; Uric Acid; Young Adult | 2012 |
A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress.
Topics: Administration, Oral; Animals; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Fructose; Glutathione; Hyperglycemia; Hyperuricemia; Insulin; Insulin Resistance; Liver; Losartan; Male; Metabolic Syndrome; Methyldopa; Oxidative Stress; Rats; Rats, Wistar; Streptozocin; Thioctic Acid; Uric Acid | 2013 |
Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular System; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Kidney Function Tests; Linear Models; Losartan; Male; Middle Aged; Proteinuria; Uric Acid | 2012 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Logistic Models; Losartan; Male; Middle Aged; Multivariate Analysis; Olmesartan Medoxomil; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2013 |
[A new application for well-known pharmaceutics--losartan and fenofibrate as potential remedies against gout?].
Topics: Angiotensin II Type 1 Receptor Blockers; Fenofibrate; Gout; Gout Suppressants; Humans; Hypolipidemic Agents; Losartan; Off-Label Use; Treatment Outcome; Uric Acid | 2014 |
Influence of losartan intake on the circadian rhythm of melatonin secretion in humans.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Cell Count; Blood Pressure; Circadian Rhythm; Female; Humans; Losartan; Male; Melatonin; Sodium; Uric Acid; Young Adult | 2014 |
Effects of losartan on expression of monocyte chemoattractant protein-1 (MCP-1) in hyperuricemic nephropathy rats.
Topics: Animals; Chemokine CCL2; Dose-Response Relationship, Drug; Hyperuricemia; Kidney; Kidney Diseases; Losartan; Male; Rats; Rats, Sprague-Dawley; Uric Acid | 2015 |
Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model.
Topics: Animals; Antihypertensive Agents; Aorta; Atherosclerosis; Blotting, Western; Disease Models, Animal; Endothelium, Vascular; Hyperuricemia; Immunohistochemistry; Lipoproteins, LDL; Losartan; Male; Microscopy, Electron, Transmission; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Uric Acid | 2015 |
Effects of Uric Acid on the NO Production of HUVECs and its Restoration by Urate Lowering Agents.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzbromarone; Biphenyl Compounds; Cells, Cultured; Glucose Transport Proteins, Facilitative; Human Umbilical Vein Endothelial Cells; Humans; Irbesartan; Losartan; Monocarboxylic Acid Transporters; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Tetrazoles; Uric Acid; Uricosuric Agents | 2016 |
Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ.
Topics: Angiotensin II; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Gene Expression Regulation; Humans; Hypertension; Hyperuricemia; Losartan; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Rats; Receptor, Angiotensin, Type 1; Receptor, Platelet-Derived Growth Factor beta; Uric Acid | 2017 |
Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Cyclooxygenase 2; Disease Models, Animal; Humans; Hypertension; Inflammation; Losartan; Muscle, Smooth, Vascular; Proto-Oncogene Proteins; Rats; Reactive Oxygen Species; Receptor Protein-Tyrosine Kinases; Signal Transduction; Superoxides; Uric Acid | 2017 |
Cerebrovascular recovery after stroke with individual and combined losartan and captopril treatment of SHRsp.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cerebrovascular Circulation; Disease Models, Animal; Drug Combinations; Enzyme Activation; Hypertension; Infarction, Middle Cerebral Artery; Losartan; Middle Cerebral Artery; Nitric Oxide; Protein Kinase C; Rats, Inbred SHR; Rats, Inbred WKY; Renin-Angiotensin System; Time Factors; Urea; Uric Acid; Vasoconstriction | 2017 |
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Gout; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Purinergic P2Y Receptor Antagonists; Risk Factors; Uric Acid | 2018 |
Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Female; Humans; Hyperuricemia; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Time Factors; Uric Acid | 2020 |
Clinical effectiveness and safety of amlodipine/losartan-based single-pill combination therapy in patients with hypertension: Findings from real-world, multicenter observational databases.
Topics: Amlodipine; Antihypertensive Agents; Humans; Hypertension; Losartan; Treatment Outcome; Uric Acid | 2021 |
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Humans; Hypertension; Losartan; Polymorphism, Genetic; Uric Acid | 2023 |
Allisartan Isoproxil Promotes Uric Acid Excretion by Interacting with Intestinal Urate Transporters in Hyperuricemic Zebrafish (Danio rerio).
Topics: Animals; Hyperuricemia; Kidney; Losartan; Uric Acid; Zebrafish | 2023 |